Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the KBS first quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker for today, Ms. Mercedes Carrasco, Senior Director of Investor Relations. Please go ahead. Thank you, and welcome to Atebia's first quarter 2025 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, May 8th, detailing our first quarter 2025 financial results, and that release is available on the investor section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, Nicholas Grund, Chief Commercial Officer, and Eric Ostrowski, Chief Financial and Chief Business Officer. I'd like to remind everyone that this call includes forward-looking statements, Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks are included in the financial results press release that we issued on May 8th, as well as in the risk factors and management discussion and analysis section of our most annual report and quarterly reports filed wi...